SSRI antidepressants and psilocybin.
7 records in this group. 6 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-25SSRIs are the medication class most studied with psilocybin. In an online survey, reports from people taking SSRIs often described psilocybin's effects as weaker than expected, including some reports after the SSRI had been stopped (Gukasyan 2023); Reddit posts show the same pattern (Sakai 2024). With LSD, 28 of 32 people who had taken an SSRI or trazodone for more than 3 weeks reported a reduced or absent response in a retrospective questionnaire (Bonson 1996).
In a randomized crossover study, 23 healthy adults took escitalopram for 14 days before psilocybin 25 mg. Compared with placebo pretreatment, positive mood effects were unchanged, and anxiety and rises in blood pressure were smaller; the authors note that longer pretreatment and studies in patients are still needed (Becker 2022). In an open-label trial without a comparison group, 19 people with treatment-resistant depression took psilocybin 25 mg while continuing an SSRI, with no serious adverse events (Goodwin 2023).
One systematic review describes serotonin toxicity from psilocybin as unlikely, because psilocybin causes little serotonin release (Sarparast 2022); another found no serious adverse events with antidepressants apart from a few case reports (Halman 2024). Unlikely is not the same as impossible: the published data are small, and rare reactions may not yet have been seen.
Stopping an antidepressant, especially suddenly, can cause withdrawal (discontinuation) symptoms or a return of depression (Zoloft prescribing information). Most clinical trials required stopping SSRIs before enrollment (Tap 2025), and later analyses of trial data differ on whether stopping changes the response to psilocybin (Erritzoe 2024; Marwood 2024).
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
- Sakai K, Bradley ER, Zamaria JA, et al. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology 2024;241(8):1617–1630.
- Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
- Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895.
- Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
- Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
- Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
- Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
- Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470.
- Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203.
- Zoloft (sertraline) prescribing information, sections 2 and 14 (DailyMed)
Also searched as SSRI · SSRIs · selective serotonin reuptake inhibitor
01 What the evidence covers
Best evidence available per medication| 1 | Controlled trial |
| 5 | Open-label trial |
| 1 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZDepression (major depressive disorder)
SSRIs often weakened psilocybin's effects in real-world reports; one trial found effects largely kept. Serotonin syndrome is unlikely, not impossible. Stopping suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Generalized anxiety disorder
In one controlled study, escitalopram kept psilocybin's positive mood effects and reduced anxiety and blood pressure rises. Stopping it suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)
Antidepressants like this often made psilocybin feel weaker in real-world reports, and fluoxetine lingers for weeks. Stopping it suddenly after regular use can cause relapse.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Obsessive-compulsive disorder (OCD)
SSRIs often made psilocybin feel weaker in real-world reports; fluvoxamine may also slow how the body clears psilocybin.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression; Obsessive-compulsive disorder (OCD)
SSRIs like paroxetine often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Obsessive-compulsive disorder (OCD)
SSRIs like sertraline often made psilocybin feel weaker; serotonin syndrome is considered unlikely, not impossible. Stopping it suddenly can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (adults)
It acts on serotonin and may make psilocybin feel weaker, as SSRIs do. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 7 | Dehydration or electrolyte risk |
| 7 | Lowers seizure threshold or carries seizure risk |
| 7 | Psychiatric reactions |
| 7 | Serotonergic |
| 7 | Withdrawal or rebound if stopped abruptly |
| 5 | QT-prolonging |
| 1 | Anticholinergic |
| 1 | Liver injury |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. Every medication in this group is psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- Antidepressants7 shared
Records reviewed 2026-10-14 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z